Clinical Trial Update: Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and tolerability of PRO-230 Ophthalmic Solution for myopia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• PRO-230 Ophthalmic Solution

Snippet

Sponsor: Laboratorios Sophia S.A de C.V. | Conditions: Myopia | Phase 1 | Status: WITHDRAWN